Genfit(US:GNFT) Globenewswire·2026-02-26 17:00Core Viewpoint - GENFIT, a biopharmaceutical company focused on rare liver diseases, reported its fourth quarter 2025 financial results, highlighting a decrease in revenues and a strong cash position to support ongoing research and development efforts. Cash Position - As of December 31, 2025, the company's cash and cash equivalents were €101.1 million, an increase from €81.8 million at the end of 2024 but a decrease from €119.0 million as of September 30, 2025 [2][4]. - Cash utilization in 2025 was primarily due to research and development activities in the Acute on-Chronic Liver Failure (ACLF) franchise and cholangiocarcinoma (CCA) programs [3]. Revenue - Total revenues for 2025 were €65.4 million, down from €67.0 million in 2024 [6]. - Royalty revenue increased significantly to €21.8 million in 2025, compared to €2.7 million in 2024, driven by worldwide sales of Iqirvo® (elafibranor), which reached $208 million [7]. - Milestone revenue decreased to €43.6 million in 2025 from €48.7 million in 2024, with significant contributions from the Ipsen Agreement [8][9]. Corporate Update and Program Highlights - The company is advancing its lead program G1090N, which has shown promising Phase 1 data, and plans to engage with regulatory authorities for a Phase 2 proof-of-concept study in ACLF [12]. - In cholangiocarcinoma, early data from the Phase 1b study of GNS561 in combination with a MEK inhibitor is encouraging, with further data expected in the first half of 2026 [12]. - Iqirvo®'s net sales for Q4 2025 were $88 million, contributing to a total of $208 million for the year, which triggered a €17.0 million milestone payment to GENFIT [12].